Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.
about
Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products.Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeysClinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertensionClinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertensionEffects of prostaglandin analogues on aqueous humor outflow pathways.Characterization of a rabbit kidney prostaglandin F(2{alpha}) receptor exhibiting G(i)-restricted signaling that inhibits water absorption in the collecting duct.Effect of topical anti-glaucoma medications on late pupillary light reflex, as evaluated by pupillometry.In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytesTopical prostaglandin analogues and conjunctival inflammation in uveitic glaucomaConjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride.Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study.Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patientsTravoprost in the management of open-angle glaucoma and ocular hypertensionUpdate on the mechanism of action of topical prostaglandins for intraocular pressure reduction.In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells.Diurnal intraocular pressure with bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in healthy subjects.Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides.Tafluprost: a novel prostaglandin analog for treatment of glaucoma.A review of the use of latanoprost for glaucoma since its launch.Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease.The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection.Human T lymphoblast cell line expresses FP receptor.Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea.Topical prostaglandin analogue drugs inhibit adipocyte differentiation.Effects of latanoprost, timolol and GLC756, a novel dopamine D(2) agonist and D(1) antagonist on LTC(4) release after rat mast cell activation.Unoprostone activation of BK (KCa1.1) channel splice variantsTafluprost for the reduction of interocular pressure in open angle glaucoma and ocular hypertension.Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations.The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient miceLevels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataractTravoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.PGE2 promotes Ca2+-mediated epithelial barrier disruption through EP1 and EP4 receptors in Caco-2 cell monolayers.Protein expression, biochemical pharmacology of signal transduction, and relation to intraocular pressure modulation by bradykinin B₂ receptors in ciliary muscle.Regeneration of optic nerve fibers with unoprostone, a prostaglandin-related antiglaucoma drug, in adult cats.PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia.Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost.Intraocular metabolites of isopropyl unoprostone.FR-190997, a nonpeptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys.Evaluation of Efficacy and Safety of Latanoprost/Timolol versus Travoprost/Timolol Fixed Combinations for Ocular Hypertension Associated with Uveitis.
P2860
Q30588260-172DC208-172F-43E6-A58F-A21BF2601283Q33626299-AA04D7BA-1D1D-4921-BDE6-2EE515D4BCD8Q33774236-97C29B5B-A93C-4D01-B0AB-B791762FAC01Q34043309-926B3FB7-E68A-45F4-B3FB-949C52388976Q34393424-C81901F6-549A-433F-8A22-D6C6B1FBE7BAQ34442417-4A17441A-DEA7-4210-B8EA-50CAB5C76146Q35550289-716F6101-1B6C-487B-86B6-9F820E53E98CQ35860207-96187BF4-571F-4024-A15B-084C9C12513EQ36192495-C08426A3-C411-4233-B475-3E02716536D6Q36940995-38FF1FCB-A1D5-4C3E-BAA5-351726B234F2Q36985297-7ABBF4B7-FBFF-4C59-BF3B-63B1FB8E2574Q37027652-C3C3A89E-7E8C-446F-9621-C2492585A66DQ37236653-8B99BA74-2C03-44FF-8D75-D60650FE70CAQ37336299-716ADA6B-9840-42D9-9B83-77724CC2346DQ37361035-7B96DE11-0C0E-4F48-BEF7-DF813B4B8106Q37555451-75BD970F-24FF-4C20-A0BA-85145113CCF2Q37636153-08371031-A6CB-480A-8B89-465E185F36BEQ37920765-B4378BEE-F41A-4E51-9413-ECEECC25F29FQ37986149-F1AD2889-79F8-4DC2-9CDC-7A7ECA6BCDEAQ38063963-71170F49-EDF3-4ED9-AF3F-EBF75BC85E6BQ38730521-96CC7B38-0C6E-46A1-A6DE-4884A8D66C49Q39539218-4FB55907-A818-418D-9F75-ABDC94750902Q39760193-E2C1A9FE-24D0-438D-AF0E-8D8867AB7354Q40070704-3D8FE71C-3CA6-44F6-AB6B-B5C669D7975CQ40076369-33D95660-AD7D-4557-84FB-4F0194680877Q40639347-95C4BF2D-C2B1-462F-8F64-7740777C1A9BQ40938971-6B0C8C0F-AC6E-4369-90AE-417DA295572EQ41767609-FC5936DC-D87C-4468-8DE9-72607650C381Q42142740-1F5165FF-446E-42C0-BDE1-87ABC73C8E0DQ42240928-1F9E4B30-28C3-4762-A90B-B52983D7FE01Q42602131-9E7FCA0B-1FD2-4877-993B-C66E668DABFDQ43059437-E8183718-288B-4E35-B98B-89AEC7A63DE0Q43114550-9465656E-A122-4FD1-97A8-4B91AC659858Q45740062-1306616A-DB0A-4725-BA85-8E25724E2B21Q46041470-D9A9F9EA-EE0B-4433-B0FF-5319EAAF5AD3Q46527985-BF97BD3D-590C-4CE2-8254-9F1CB6F60980Q46775931-24E3E699-8432-4CE1-BD9D-6A24DFEACB65Q51748893-FFF8D082-5EBF-445E-AADF-F4C26434BA7EQ53639813-2FBBB2BC-D7D4-4808-AA9E-296901286FF6
P2860
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Ocular hypotensive FP prostagl ...... G receptors in cultured cells.
@en
type
label
Ocular hypotensive FP prostagl ...... G receptors in cultured cells.
@en
prefLabel
Ocular hypotensive FP prostagl ...... G receptors in cultured cells.
@en
P2093
P1476
Ocular hypotensive FP prostagl ...... G receptors in cultured cells.
@en
P2093
P304
P356
10.1089/108076803322660422
P577
2003-12-01T00:00:00Z